Document Detail


Indomethacin tocolysis increases postnatal patent ductus arteriosus severity.
MedLine Citation:
PMID:  9794986     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
METHODS: Medical records of all mothers and premature neonates with birth weight </=1500 g, admitted to the neonatal intensive care unit of the Shaare Zedek Medical Center during 1996 and 1997, who survived for at least 1 week, were reviewed retrospectively. Data on maternal indomethacin and steroid exposure, birth weight and gestational age, and ductus status and treatment were analyzed. In our obstetrics department, indomethacin is the medication of choice to inhibit premature labor. Mothers who arrive in premature labor are started on indomethacin therapy, if delivery is not imminent. All infants </=1500 g were studied by a pediatric cardiologist between 24 and 72 hours of life using two-dimensional echocardiography with color flow mapping to assess ductal patency. Decisions to treat were based on echocardiographic evidence of PDA, along with any of the following clinical signs: bounding pulses, diastolic pressure of </=25 mm Hg, pulmonary plethora and/or cardiomegaly on chest x-ray, or increasing oxygen requirement with no other explanation. Initial treatment is with indomethacin, if there are no contraindications. Our general approach is to begin therapy with a continuous indomethacin infusion, followed by a course of bolus indomethacin if the infant does not respond. However, each attending neonatologist may treat according to his/her preference (ie, bolus vs continuous). All infants with PDA are followed with serial echocardiographic examinations until the ductus is closed.
RESULTS: A total of 105 premature infants met the above criteria. Thirty-six of these 105 infants had echocardiographic signs of a PDA (34.3%). Those with PDA were less mature (gestational age, 28.9 +/- 2.6 vs 30.3 +/- 2.6 weeks, respectively) and tended to be smaller (1060 +/- 270 vs 1166 +/- 261 g). Of the 36 infants with PDA, 15 (42%) resolved spontaneously and 21 (58%) were symptomatic and required treatment with indomethacin. There were no differences in gestational age or birth weight between infants whose PDA resolved spontaneously and those requiring indomethacin therapy. Four of the 21 (19%) treated infants remained unresponsive to indomethacin and required ductal ligation. Of 17 infants with PDA who responded to indomethacin therapy, 1 (6%) was treated with a single course of bolus indomethacin, to which he responded, and 16 (94%) were treated with continuous indomethacin and responded promptly. The differences in therapeutic responsiveness to initial treatment with continuous vs bolus indomethacin were not significant. Of the 105 infants, 29 were exposed to indomethacin tocolysis. Those who were exposed to antenatal indomethacin and those who were not were well-matched with respect to birth weight and gestational age. Fifteen (52%) of the 29 exposed infants versus 18 (24%) of the 76 infants not exposed to antenatal indomethacin developed a PDA postnatally (relative risk = 2.1; 95% confidence interval: 1.22-3.74), and 45% of the antenatally exposed infants versus 12% of the nonexposed infants were symptomatic and required indomethacin (relative risk = 1.9; 95% confidence interval: 1.17-3.20). Four of the exposed infants versus none of the unexposed infants required surgical ligation. (ABSTRACT TRUNCATED)
Authors:
C Hammerman; J Glaser; M Kaplan; M S Schimmel; B Ferber; A I Eidelman
Related Documents :
11877636 - Energy expenditure in ill premature neonates.
7351906 - Effect of fluid administration on the development of symptomatic patent ductus arterios...
776196 - Ligation of patent ductus arteriosus in premature infants.
6204696 - Intestinal transmission of macromolecules (bsa and fitc-labelled dextrans) in the neona...
17466716 - Umbilical blood flow during pregnancy: evidence for decreasing placental perfusion.
7909236 - Neonatal superficial cerebral arteriovenous malformations.
Publication Detail:
Type:  Journal Article    
Journal Detail:
Title:  Pediatrics     Volume:  102     ISSN:  1098-4275     ISO Abbreviation:  Pediatrics     Publication Date:  1998 Nov 
Date Detail:
Created Date:  1998-11-06     Completed Date:  1998-11-06     Revised Date:  2013-05-20    
Medline Journal Info:
Nlm Unique ID:  0376422     Medline TA:  Pediatrics     Country:  UNITED STATES    
Other Details:
Languages:  eng     Pagination:  E56     Citation Subset:  IM    
Affiliation:
Department of Neonatology, Shaare Zedek Medical Center, Jerusalem, Israel.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Ductus Arteriosus, Patent / chemically induced*,  classification,  drug therapy
Female
Humans
Indomethacin / adverse effects*,  therapeutic use
Infant, Newborn
Infant, Premature
Infant, Premature, Diseases / chemically induced*,  classification,  drug therapy
Obstetric Labor, Premature / drug therapy
Pregnancy
Regression Analysis
Retrospective Studies
Risk Factors
Severity of Illness Index
Tocolysis
Tocolytic Agents / adverse effects*,  therapeutic use
Chemical
Reg. No./Substance:
0/Tocolytic Agents; 53-86-1/Indomethacin

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Exposure to and compliance with pediatric injury prevention counseling--United States, 1994.
Next Document:  Dad, may I have the keys? Factors influencing which vehicles teenagers drive.